Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2011

BC Cancer Agency Buys RainDance’s ThunderStorm High-Throughput Sequencing System

  • The British Columbia Cancer Agency has purchased from RainDance Technologies a new ThunderStorm™ system for high-throughput targeted sequencing of cancer predisposition genes. The fully-automated solution enables researchers to process up to 96 samples per run.

    BC Cancer Agency anticipates using the ThunderStorm system over the next two years in its quest to sequence a large number of samples from patients with hereditary predisposition to various cancers.

    The agency’s development of a high-throughput clinical next-generation sequencing pipeline has won support from the Provincial Health Services Authority, BC Cancer Foundation, and Genome BC.

    The ThunderStorm system simultaneously processes millions of individual single molecule PCR reactions by encapsulating each reaction in separate aqueous droplets, using RainDance’s microdroplet-based technology. The system supports a range of targeted sequencing applications including candidate gene lists, regions of association, signaling pathways, and deep sequencing of heterogeneous tumor samples.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »